Palmitoyl Dipeptide-6

Dosing from the Literature

Published for skin: nothing; the 1–4% in serums is what ingredient suppliers list. Not published: any trial of it.

As a cosmetic ingredient, Palmitoyl Dipeptide-6 has no dose in the drug sense, only a percentage of the finished product. Ingredient suppliers' technical dossiers list these inclusion levels:

The inclusion percentages above are what ingredient suppliers' dossiers list. No dose-response study of Palmitoyl Dipeptide-6 in human skin has been published, so no concentration has been shown to work. For comparison, a 12-week trial of Matrixyl's peptide used 3 ppm pal-KTTKS (0.0003%) in a moisturizer, given to 93 Caucasian women aged 35–55 (Robinson et al., 2005).

What It Is

This page uses the name Palmitoyl Dipeptide-6 for palmitoyl-Val-Trp (pal-VW), a cosmetic dipeptide (a chain of 2 amino acids) with a 16-carbon palmitic acid tail; such tails make short peptides amphiphilic (Castelletto et al., 2013), and the Sederma group reported that they improve skin penetration (Lintner & Peschard, 2000). The name is not in the European Commission's cosmetic-ingredient database, CosIng, which lists the valine–tryptophan dipeptide as Dipeptide-2 and defines Dipeptide-6 as proline–hydroxyproline (CosIng, read October 3, 2026). Related supplier-branded materials under the INCI "Palmitoyl Dipeptide-6 Diaminohydroxybutyrate" (a different chemical entity used in products such as Sederma's Syn-Tacks and Syn-Ake-adjacent blends) share the "Palmitoyl Dipeptide-6" prefix but are chemically distinct and frequently confused with the plain pal-Val-Trp material.

The broader class — palmitoylated cosmetic peptides — was established commercially in the late 1990s and early 2000s when Sederma introduced Matrixyl (palmitoyl pentapeptide-3, later renamed palmitoyl pentapeptide-4 in 2006, sequence palmitoyl-KTTKS) as a topical analog of a pro-collagen I carboxy-terminal fragment first shown to stimulate fibroblast (a cell that builds collagen) ECM production by Katayama and colleagues in 1993 (PMID 8486721). The strategic logic was explicit: take a short, biologically interesting peptide sequence; attach a palmitic acid chain to overcome stratum-corneum exclusion of polar low-molecular-weight peptides; formulate into a topical vehicle; and market the ingredient to finished-product brands as a "signal peptide" that engages fibroblasts to produce more collagen, elastin, and fibronectin. Palmitoyl Dipeptide-6 belongs to this same strategic family — it is shorter (two amino acids rather than five) and is marketed by multiple cosmetic peptide suppliers as a skin-firming active, at the 1–4% of a finished formulation that their dossiers list.

Unlike Matrixyl, for which the underlying pentapeptide (a chain of 5 amino acids) KTTKS has decades of fibroblast-ECM in vitro data, Palmitoyl Dipeptide-6 (pal-VW) does not have a comparable body of independent biochemistry behind it. Valine-tryptophan is not a canonical matrikine (a signaling fragment from broken-down skin matrix) motif recognized in the peer-reviewed dermatological literature; supplier dossiers cite internal in-vitro experiments (proprietary fibroblast assays, gene-expression panels, ex-vivo skin explant measurements) to substantiate mechanism claims. In practice, the pal-VW active is marketed on the twin pillars of (1) the palmitoylation delivery story that applies to the entire cosmetic-lipopeptide class and (2) generic signal-peptide language extrapolated from Matrixyl, Rigin, and copper peptide literature.

The supplier landscape is fragmented. Palmitoyl Dipeptide-6 (and the distinct Palmitoyl Dipeptide-6 Diaminohydroxybutyrate material) is produced by several cosmetic peptide manufacturers including Sederma (a Croda company), DSM/Pentapharm, Lipotec/Lubrizol adjacent suppliers, and multiple Asian peptide-synthesis houses that supply ingredient-level material to finished-product brands. No single manufacturer owns the INCI exclusively. This differs sharply from branded actives like Argireline (acetyl hexapeptide-8, Lubrizol) or Matrixyl (Sederma) where a single supplier controls the narrative and publishes the sponsored in-vivo supporting data. The diffuse supplier landscape for Palmitoyl Dipeptide-6 partly explains the thin published record — no single party has had the commercial incentive to fund, execute, and publish a peer-reviewed RCT on a finished product whose primary claim hinges on this specific INCI.

Mechanism of Action

Palmitoyl Dipeptide-6's mechanism claims are drawn from the general pharmacology of cosmetic lipopeptides plus supplier-dossier in-vitro data. None has been tested on this compound in a peer-reviewed study (PubMed lists no study of it).

• Palmitoyl delivery strategy (class-level) — A C16 palmitic-acid tail turns a short peptide into an amphiphile (Castelletto et al., 2013). The Sederma group reported that such tails improve skin penetration: in diffusion-cell tests, palmitoyl carnosine reached the epidermis and dermis while plain carnosine stayed in the stratum corneum, and neither crossed the skin in significant amounts (Lintner & Peschard, 2000; summarized in CIR 2012). For KTTKS and its palmitoylated form, a review found almost no in-vitro skin-penetration data (Abu Samah & Heard, 2011; PMID 21535443). The palmitoyl tail is what pal-VW has in common with these lipopeptides; pal-VW itself has not been tested.
• Claimed fibroblast stimulation (supplier-dossier) — Marketing documents from cosmetic peptide suppliers cite in-vitro fibroblast assays in which Palmitoyl Dipeptide-6 is reported to increase expression of extracellular-matrix genes (procollagen I, procollagen III, fibronectin, elastin). None has been published in a peer-reviewed journal (PubMed lists no study of it), and how much of any such peptide reaches fibroblasts through skin is largely unmeasured: a review of KTTKS found almost no skin-penetration data (Abu Samah & Heard, 2011).
• Claimed ECM / matrix-supportive signaling — Supplier literature positions Palmitoyl Dipeptide-6 as engaging TGF-β pathway signaling and integrin-associated matrix remodeling. No published study has tested pal-VW on TGF-β receptors, SMAD transcription factors or any other pathway in skin cells.
• Theoretical procollagen messaging — By analogy to KTTKS (a subfragment of the C-terminal propeptide of type I procollagen that stimulated collagen and fibronectin production in cultured cells; Katayama et al., 1993), supplier narratives position short peptide fragments as "matrikines" capable of mimicking endogenous procollagen-derived messengers. Valine-tryptophan is not a published procollagen-derived matrikine, so this framing is a conceptual appeal rather than a mechanism demonstrated for pal-VW specifically.
• Comparison with Matrixyl (palmitoyl pentapeptide-4, pal-KTTKS) — Matrixyl has at minimum Robinson et al. 2005 (PMID 18492182) as a 12-week split-face RCT in 93 women showing fine-line reduction at 3 ppm pal-KTTKS versus moisturizer control. Palmitoyl Dipeptide-6 has no clinical trial (PubMed lists no study of it). Both carry a palmitoyl tail; clinically, pal-KTTKS has relatively few studies (Abu Samah & Heard, 2011), and Palmitoyl Dipeptide-6 has none.
• Comparison with Argireline (acetyl hexapeptide-8) — A different mechanism class: in laboratory tests it interfered with the SNARE complex that drives neurotransmitter release (Blanes-Mira et al., 2002), and it is described as a competitive SNAP-25 inhibitor (Lungu et al., 2012). Argireline has a published mechanism paper with a small volunteer test (Blanes-Mira et al., 2002) and a 24-patient pilot trial (Lungu et al., 2012). Palmitoyl Dipeptide-6 is not marketed for neuromuscular effects: it sits in the signal-peptide category, not the neurotransmitter-affecting one, of the three categories of cosmetic peptides (Lupo & Cole, 2007).
• Comparison with Copper GHK-Cu — Copper tripeptide is among the well-documented cosmetic peptides still under study (Schagen, 2017). Palmitoyl Dipeptide-6 shares the general "signal peptide" framing but has no published mechanism study at all.
• Self-assembly behavior — Palmitoyl lipopeptides (including pal-KTTKS, pal-GHK, pal-KT) are amphiphilic molecules that self-assemble above a critical aggregation concentration, pal-KTTKS into flat tapes and fibrils and pal-GHK and pal-KT into crystal-like aggregates (Castelletto et al., Langmuir 2013). The authors suggest the aggregates may bear on these peptides' reported collagen effects; that has not been tested. They found the critical aggregation concentration was governed by the lipid chain length; pal-VW carries the same C16 chain but has not itself been studied.
• TGF-β speculation — The supplier claim that Palmitoyl Dipeptide-6 acts through TGF-β signaling to support ECM deposition is a hypothesis: no published study has tested it, in skin biopsies, gene-expression analyses or cells.
• Not marketed as a neurotransmitter-affecting peptide — Supplier claims for Palmitoyl Dipeptide-6 are signal-peptide claims, not "botox-like" ones. No study has tested it on SNAP-25 (a core protein in the machinery that releases neurotransmitters at nerves), the SNARE complex (the machinery that releases neurotransmitters), acetylcholine release or any neuromuscular pathway.

What the Research Shows

The honest summary: almost nothing. Palmitoyl Dipeptide-6 does not have a peer-reviewed clinical research base of its own. The evidence that exists is drawn from the broader cosmetic lipopeptide category, from supplier marketing dossiers, and from mechanistic inference — none of which is a substitute for an independent randomized controlled trial of a finished product.

• No published finished-product RCT — A PubMed search in April 2026 for clinical trials in which Palmitoyl Dipeptide-6 is the primary active returns no independent peer-reviewed randomized controlled trial. This is in contrast to Matrixyl (Robinson 2005, PMID 18492182), Argireline (Blanes-Mira 2002 and subsequent small trials), and copper peptides (multiple in-vivo studies) — each of which has at least one real published clinical paper, however methodologically limited.
• Category-level support from Matrixyl (pal-KTTKS) — Robinson et al. 2005 (PMID 18492182) enrolled 93 Caucasian women aged 35–55 in a 12-week split-face double-blind placebo-controlled trial. Moisturizer with 3 ppm pal-KTTKS produced statistically significant reduction in fine lines and wrinkles versus moisturizer control by both quantitative image analysis and expert-grader assessment. This trial does not speak to Palmitoyl Dipeptide-6 efficacy directly — it speaks only to the broader palmitoyl-lipopeptide-in-moisturizer delivery strategy at low parts-per-million inclusion levels.
• KTTKS in-vitro substrate — Katayama et al. 1993 (PMID 8486721) found that the pentapeptide KTTKS (residues 212–216 of the type I procollagen C-terminal propeptide) is the minimum sequence needed to stimulate collagen and fibronectin production in a variety of mesenchymal cells. This is the founding biochemistry of the matrikine concept for cosmetic signal peptides. It is evidence about KTTKS, not about Val-Trp.
• Palmitoylation-enhances-permeation literature — The Sederma group reported that fatty-acid tails improve peptides' skin penetration (Lintner & Peschard, 2000). The Cardiff group's review of topically applied KTTKS found almost no in-vitro skin-penetration data for it or its derivatives (PMID 21535443), and Hamley and collaborators studied how palmitoyl lipopeptides self-assemble, not how they cross skin (Castelletto et al., 2013). Whether pal-VW reaches living skin cells, or does anything there, has not been tested.
• Argireline precedent — Blanes-Mira et al. 2002 established acetyl hexapeptide-3 (now acetyl hexapeptide-8) as a topical SNAP-25 mimetic in a proof-of-concept cosmetic-ingredient paper. Subsequent small trials (a 24-patient blepharospasm pilot, PMID 23146065, and multiple small efficacy studies summarized in the 2025 PMC12193160 review) demonstrate that a cosmetic peptide active with a clearly defined molecular mechanism can accrue a modest but real clinical literature. Palmitoyl Dipeptide-6 has not yet accrued anything comparable.
• Cosmeceutical peptide reviews — Lupo & Cole 2007 (PMID 18045359) and Schagen 2017 (MDPI Cosmetics 4(2):16) survey the cosmetic peptide field and classify palmitoyl lipopeptides as "signal peptides" with modest but real topical evidence for the leading members of the class. Neither review identifies Palmitoyl Dipeptide-6 as an ingredient with independent clinical substantiation — both mention it, if at all, as part of the broader lipopeptide category.
• Sensitive-skin usage analysis — A 2021 analysis of 88 facial cosmetic products for sensitive skin found that palmitoyl tripeptide-5, palmitoyl tetrapeptide-7, and palmitoyl oligopeptide appeared in at least one product each; Palmitoyl Dipeptide-6 was not among the most-used peptides identified in that survey, consistent with its lower market penetration relative to Matrixyl-family actives and Argireline.
• Oral collagen peptide literature is not relevant — Proksch 2014 (PMID 23949208) and the broader oral collagen peptide RCT literature address gastrointestinal-absorbed collagen hydrolysate, which bears no mechanistic relationship to a topical lipopeptide like Palmitoyl Dipeptide-6. It is cited here only to flag a common conflation: being a "peptide" does not make oral collagen peptide evidence transferable to topical lipopeptide marketing claims.
• CIR safety assessment — The Cosmetic Ingredient Review's 2012 document on palmitoyl oligopeptides (CIR 2012) is a scientific literature review, with no Panel conclusion; it covers palmitoyl dipeptide-7, -10, -13, -17 and -18, but not Palmitoyl Dipeptide-6. CIR's 2018 final report on related peptides concluded that tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 are safe in cosmetics as used. Palmitoyl Dipeptide-6 is not in CIR's ingredient index (read October 3, 2026).

Human Data

There is essentially no peer-reviewed human clinical trial data specific to Palmitoyl Dipeptide-6. PubMed, ClinicalTrials.gov, and EU Clinical Trials Register do not list a completed randomized controlled trial of a topical finished product in which Palmitoyl Dipeptide-6 is the named primary active. The following paragraphs describe the category human data (relevant to the palmitoyl-lipopeptide class as a whole) and the manufacturer-dossier human data (proprietary, not peer-reviewed, not independently verifiable).

• Matrixyl pivotal trial (PMID 18492182) — Robinson 2005. 93 Caucasian women, aged 35–55, 12-week split-face double-blind placebo-controlled design. Moisturizer with 3 ppm pal-KTTKS vs. same moisturizer without pal-KTTKS. Primary endpoints: fine-line density, wrinkle depth by quantitative image analysis, expert-grader rating. Result: statistically significant wrinkle reduction in the pal-KTTKS arm. This is the strongest finished-product evidence in the palmitoyl-lipopeptide class.
• KTTKS fibroblast biochemistry (PMID 8486721) — Katayama 1993. The foundational in-vitro demonstration that the pentapeptide KTTKS (a procollagen I C-terminal propeptide fragment) increases collagen I, collagen III, and fibronectin production in fibroblast cultures. Not human in-vivo data, but the mechanistic anchor for the entire signal-peptide cosmetic-ingredient category.
• Acetyl hexapeptide-8 topical blepharospasm trial (PMID 23146065) — Small 2012 pilot in patients receiving botulinum neurotoxin for blepharospasm, testing topical acetyl hexapeptide-8 as an adjunct: in 24 patients it caused no significant adverse events and showed a trend toward longer symptom control (3.7 vs 3.0 months). Tangentially relevant for cosmetic signal-peptide category framing; not directly relevant to Palmitoyl Dipeptide-6.
• Topically applied KTTKS review (PMID 21535443) — Abu Samah and Heard 2011. Comprehensive review of KTTKS and its major derivatives (including pal-KTTKS Matrixyl) covering physicochemical properties, theoretical skin permeation, and published evidence. Useful for understanding the class-level pharmacokinetic rationale for lipopeptide cosmetic actives.
• Biologically active peptides cosmetic review (PMID 18503476) — Lintner & Peschard 2000. The foundational review paper from Sederma's chief researcher establishing the cosmetic-peptide conceptual framework. Describes the palmitoylation strategy, matrikine concept, and chemotaxis (cell migration toward a signal) / anti-stinging effects. Not Palmitoyl Dipeptide-6-specific but establishes the supplier-dossier vocabulary that pal-VW marketing inherits.
• Cosmeceutical peptides dermatologic review (PMID 18045359) — Lupo & Cole 2007. Three-category classification (signal, neurotransmitter-affecting, carrier) of cosmetic peptides. Notes the limited rigor of efficacy testing for the class as a whole — a theme that applies acutely to Palmitoyl Dipeptide-6.
• Oral collagen peptide RCT (PMID 23949208) — Proksch 2014. Oral hydrolyzed collagen peptide randomized trial. Cited here solely to clarify that oral collagen peptide evidence is not transferable to topical lipopeptide efficacy claims; consumers and marketing copy frequently conflate these literatures.
• Manufacturer dossier-level human data — Multiple cosmetic peptide suppliers (Sederma, DSM/Pentapharm, Lipotec, and smaller Asian suppliers) maintain internal panel-test and consumer-perception data on Palmitoyl Dipeptide-6 and related lipopeptide actives. These are not peer-reviewed, typically involve small single-arm consumer panels (n = 20–40), and report self-reported skin-feel improvement rather than objective endpoints. They do not constitute clinical evidence in the sense required by drug regulatory authorities, and they are not RCT data.
• Post-market pharmacovigilance — None published: Palmitoyl Dipeptide-6 has no CIR safety report and no CosIng entry (both read October 3, 2026).
• ClinicalTrials.gov search (April 2026) — No registered prospective clinical trial for Palmitoyl Dipeptide-6 as intervention or as component of the primary intervention product. Contrast: Matrixyl and acetyl hexapeptide-8 each have multiple registrations, though quality and completion rates are mixed.

The bottom line for human data: no study of Palmitoyl Dipeptide-6 in people has been published, for safety or for effect, and it has no CIR safety report or CosIng entry (both read October 3, 2026).

Reconstitution & Storage

Palmitoyl Dipeptide-6 is sold as a cosmetic ingredient for creams and serums, not as a vial to mix. No published study gives handling or storage figures for it.

• No injectable form — Palmitoyl Dipeptide-6 is not an approved drug and has not been tested by injection (PubMed lists no study of it).

→ Calculator — vial-to-syringe math

Side Effects & Risks

No study of Palmitoyl Dipeptide-6 has been published (PubMed lists none), so none of its side effects has been measured. The Cosmetic Ingredient Review (CIR) has not assessed it: it is not in CIR's ingredient index, and CIR's 2012 literature review of palmitoyl oligopeptides did not list it (CIR 2012).

• Irritation and allergy (not studied) — No irritation or allergy test of it has been published. CIR's 2012 review found no published irritation or sensitization studies of palmitoyl peptides (CIR 2012); in the pal-KTTKS trial, 93 women tolerated it well (Robinson et al., 2005), and topical acetyl hexapeptide-8 caused no significant adverse events in 24 patients (Lungu et al., 2012).
• Pregnancy and lactation — No data: it has not been studied in pregnancy or breastfeeding, and CIR's 2012 review found no reproductive or developmental toxicity data for palmitoyl oligopeptides (CIR 2012).
• Pediatric use — No safety or efficacy data in children.
• No systemic safety data — Palmitoyl Dipeptide-6 has not been evaluated for oral or parenteral safety, and how much of it passes through skin has not been measured.
• Drug interactions (topical) — None studied.
• Self-assembly behavior — Palmitoyl peptides used in skin care self-assemble above a critical aggregation concentration, into flat tapes and fibrils (pal-KTTKS) or crystal-like aggregates (pal-GHK, pal-KT) (Castelletto et al., 2013). Pal-VW has not been tested.
• Comparison to botulinum toxin — The "alternative to botulinum toxin" framing belongs to Argireline (acetyl hexapeptide-8), whose developers called it "a biosafe alternative to BoNTs in cosmetics" (Blanes-Mira et al., 2002); supplier claims for Palmitoyl Dipeptide-6 are signal-peptide claims.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for Palmitoyl Dipeptide-6, and no study of it in people has been published (PubMed lists none).

• No concern for athletes — Palmitoyl Dipeptide-6 is not on the WADA Prohibited List and topical cosmetic use presents no doping-monitoring concern.

Commonly Stacked With

No published study tests Palmitoyl Dipeptide-6 with any other ingredient; PubMed lists no study of it at all.

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching Palmitoyl Dipeptide-6 often also look at these:

Next Steps

References

1. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The foundational 93-woman split-face RCT of pal-KTTKS 3 ppm — the strongest finished-product evidence in the palmitoyl-lipopeptide cosmetic class and the category anchor for lipidated signal-peptide claims.)
2. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-9944. PMID: 8486721. (Founding in-vitro demonstration that the KTTKS pentapeptide stimulates type I collagen, type III collagen, and fibronectin production in fibroblast cultures — the biochemical anchor for the "matrikine" cosmetic-peptide framework.)
3. Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000;22(3):207-218. PMID: 18503476. (Sederma's foundational review establishing the cosmetic-lipopeptide strategic framework — palmitoylation for stratum-corneum delivery, matrikine concept, chemotaxis and anti-stinging effects. Reference text for supplier-dossier vocabulary.)
4. Abu Samah NH, Heard CM. Topically applied KTTKS: a review. Int J Cosmet Sci. 2011;33(6):483-490. PMID: 21535443. (Comprehensive academic review of KTTKS and its major derivatives including palmitoylated forms. Addresses physicochemical properties, theoretical skin permeation, and evidence appraisal.)
5. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Dermatology-review classification of cosmetic peptides into signal, neurotransmitter-affecting, and carrier categories. Notes the limited efficacy-testing rigor of the field as a whole.)
6. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics (MDPI). 2017;4(2):16. DOI: 10.3390/cosmetics4020016. (Peer-reviewed open-access survey of cosmeceutical peptides against intrinsic and extrinsic aging — places palmitoyl lipopeptides in the signal-peptide category and summarizes class-level evidence.)
7. Castelletto V, Hamley IW, Whitehouse C, Matts PJ, Osborne R, Baker ES. Self-Assembly of Palmitoyl Lipopeptides Used in Skin Care Products. Langmuir. 2013;29(29):9149-9155. DOI: 10.1021/la401771j. (Biophysical characterization of pal-KTTKS, pal-GHK, and pal-KT self-assembly — establishes that palmitoyl cosmetic lipopeptides form β-sheet nanotape and micellar structures above critical aggregation concentration, with implications for in-vehicle behavior.)
8. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernandez-Ballester G, Ponsati B, Gutierrez L, Perez-Paya E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. DOI: 10.1046/j.1467-2494.2002.00153.x. (Founding mechanism paper for acetyl hexapeptide-8 — cited here as a methodological comparison for a cosmetic-peptide active with a defined molecular mechanism, to contrast with Palmitoyl Dipeptide-6's thinner mechanistic record.)
9. Cosmetic Ingredient Review Expert Panel. Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics. CIR. 2012. (Class-level cosmetic-ingredient safety assessment covering palmitoyl oligopeptides including palmitoyl dipeptide class entries. Available via cir-safety.org. Establishes the safety floor for the ingredient family.)
10. Lungu C, Considine E, Zahir S, et al. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. J Rehabil Med. 2012;44(10):888-891. PMID: 23146065. (Small pilot demonstrating a cosmetic peptide active's topical clinical utility — tangentially relevant category context for topical-peptide clinical-evidence expectations.)
11. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. DOI: 10.1111/j.1468-2494.2009.00490.x. (Review of topical peptide cosmetics with evidence-rating discussion across the signal / neurotransmitter / carrier peptide categories. Useful framing for evaluating Palmitoyl Dipeptide-6 against class peers.)
12. Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2014;27(1):47-55. PMID: 23949208. (Oral collagen-peptide RCT cited here to clarify that oral collagen-peptide literature is not transferable to topical lipopeptide marketing — a common conflation.)
13. Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling the future. J Cosmet Dermatol. 2009;8(1):8-13. DOI: 10.1111/j.1473-2165.2009.00416.x. (Review of bioactive peptides in dermatology, including discussion of signal peptides and palmitoyl lipopeptides as the leading topical class.)
14. Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Dermatol Clin. 2009;27(4):401-416. DOI: 10.1016/j.det.2009.08.005. (Dermatology-clinic practical review covering cosmeceutical peptide categories and evidence appraisal for a clinician audience.)
15. Draelos ZD. Cosmeceuticals: undefined, unclassified, and unregulated. Clin Dermatol. 2009;27(5):431-434. DOI: 10.1016/j.clindermatol.2009.05.005. (Editorial framing of the cosmeceutical regulatory category — directly relevant to Palmitoyl Dipeptide-6's ambiguous regulatory classification and evidence expectations.)
16. Zhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol. 2009;27(5):485-494. DOI: 10.1016/j.clindermatol.2009.05.013. (Review specifically on cosmetic peptides from a dermatology-clinic perspective, addressing the signal-peptide class including palmitoylated variants.)
17. Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. DOI: 10.4103/0378-6323.186500. (Narrative review of topical peptide cosmeceuticals including palmitoyl lipopeptides; evaluates evidence and regulatory framework for the category.)
18. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. DOI: 10.3389/fchem.2020.572923. (Contemporary review of cosmeceutical peptide chemistry, delivery, and regulatory frameworks. Useful for placing Palmitoyl Dipeptide-6 within the modern cosmetic-peptide landscape.)
19. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)

Related Research

• AHK-CuCopper Tripeptide (Hair)
• ArgirelineSNAP-25 Mimetic
• Decapeptide-12Tyrosinase Inhibitor
• GHK BasicMatrikine / Cosmetic Signaling Peptide
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.